Abiraterone: Indication of considerable added benefit in certain patients

Abiraterone acetate is approved for treatment of metastatic prostate cancer that can no longer be treated with hormones and progresses further during or after therapy with the cytostatic drug docetaxel. IQWiG finds an indication of a considerable added benefit of abiraterone in patients who are not eligible for further treatment with docetaxel. In contrast, an added benefit is not proven in patients who can still be treated with docetaxel. Read more